Showing results (51-60 of 115) with videos related to
Sort By:
Pageof 12
Science Translational Medicine|June 14, 2013
Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumorsArina Riabinska, Mathias Daheim, Grit S Herter-Sprie, et al.Blood Advances|January 20, 2022
Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosisNico Gagelmann, Christine Wolschke, Rachel B Salit, et al.Journal of the American Society of Nephrology : JASN|July 4, 2008
KIBRA modulates directional migration of podocytesKerstin Duning, Eva-Maria Schurek, Marc Schlüter, et al.Bone Marrow Transplantation|July 11, 2021
Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMTFrédéric Baron, Maud Ngoya, Myriam Labopin, et al.Leukemia|October 14, 2022
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trialRobert Seifert, David Kersting, Christoph Rischpler, et al.European Journal of Haematology|June 29, 2021
Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvementSara Oubari, Eyad Naser, Maria Papathanasiou, et al.Oncogene|January 12, 2018
AATF suppresses apoptosis, promotes proliferation and is critical for Kras-driven lung cancerDaniela Welcker, Manaswita Jain, Safiya Khurshid, et al.Journal of Personalized Medicine|September 28, 2021
Pregnancies and Neonatal Outcomes in Patients with Sickle Cell Disease (SCD): Still a (High-)Risk Constellation?Pia Proske, Laura Distelmaier, Carmen Aramayo-Singelmann, et al.Hemasphere|June 18, 2026
Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid DiseasesAlexander Carpinteiro, Christoph Kimmich, Despina Trajanova, et al.Bone Marrow Transplantation|March 31, 2023
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMTGesine Bug, Myriam Labopin, Riitta Niittyvuopio, et al.Pageof 12